|
|
|
European Biopharmaceutical Review
|
Drug development is an arduous process punctuated by go/no-go decisions related to the efficacy and safety of drug candidates. When a new preclinical drug candidate with a reasonable profile of efficacy and safety is identified, it is still uncertain whether this new therapeutic agent will ultimately make its way to the patient and advance human health. In fact, ~90% of all compounds entering clinical trials fail, largely due to safety issues in clinical phases or drug efficacy issues in patients (1).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Judi Wardwell is a Senior Application Scientist at InSphero, with more than 25 years of experience working in the pharma industry. Prior to joining InSphero, she was the Manager of a functional genomic group at Bristol-Myers Squibb, where she developed physiologically relevant cell models and conducted phenotypic screens to identify new drug targets in developing integrated approaches to target identification. Judi has also held scientific research positions at Wyeth and Hoffmann-La Roche.
Dr Radina Kostadinova is Lead Product Manager for InSphero 3D InSight™ Liver Toxicology and Disease Platforms. She has more than 17 years of research experience in industry and academic settings, working in the fields of molecular and cellular biology and preclinical mechanistic toxicology. At InSphero, her focus is to develop and establish liver tissue models for detection of drug toxicity, as well as 3D liver disease models for the study of fibrosis, inflammation, diabetes, and obesity.
Professor Armin Wolf is Chief Scientific Officer at InSphero and Professor of Toxicology at the Technical University of Kaiserslautern, Germany. An accomplished pharma R&D executive and board-certified toxicologist with more than 30 years’ cumulative experience at Janssen and Novartis, Armin offers a first-hand perspective on the challenges facing the pharma industry and the need for more physiologically relevant human models to improve efficiency in drug discovery and safety testing.
|
|
|
Judi Wardwell |
|
|
|
|
Judi Wardwell |
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Schrödinger Announces Acquisition of XTAL BioStructures, Inc.
NEW YORK--(BUSINESS WIRE)--Jan. 18, 2022-- Schrödinger, Inc. (Nasdaq:
SDGR), whose physics-based software platform is transforming the way
therapeutics and materials are discovered, today announced the
acquisition of XTAL BioStructures, Inc., a private company based in the
Greater Boston area that provides structural biology services, including
biophysical methods, protein production and purification, and X-ray
crystallography, to the pharmaceutical and biotechnology industries.
More info >> |
|
 |
White Papers |
 |
|
The EC Definition of a Nanomaterial - Potential Measurement Methodologies
NanoSight
In October 2011 the European Commission
published a definition of Nanomaterials. This move followed more than six
years of scientific consideration of the potential toxicological and
environmental challenges posed by engineered nanomaterials.
More info >> |
|
|
.jpg)
